EEG Characteristics in ECT

University of New Mexico (UNM)

Status and phase

Completed

Early Phase 1

Conditions

Spreadind Depression

Electroconvulsive Therapy

Ketamine

Direct Current Electroencephalogram

Treatments

Drug: Ketamine

Drug: Methohexital

Study type

Interventional

Funder types

Other

Identifiers

NCT04022226

19-228

Details and patient eligibility

About

The investigators will be examining slow-wave characteristics in depressed patients receiving electroconvulsive therapy (ECT) using direct current electroencephalogram (dcEEG) by anesthesia induction agent.

Full description

This is a pilot project using dcEEG to look at infra-slow waves in depressed patients receiving ECT randomized to ketamine or methohexital where ketamine suppresses infra-slow waves. The rationale for this project is to identify biomarkers of treatment adequacy in ECT, which could lead to decreased morbidity and mortality with the procedure and lessen the burden of depression in our patient population.

Enrollment

11 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Structured Clinical Interview for DSM-5 will confirm diagnosis of MDD or BPD-depressed (with or without psychotic features
The clinical indications for ECT including treatment resistance or a need for a rapid and definitive response;
Hamilton Depression Rating Scale 24-item (HDRS-24) > 21; and
Age range between 18 and 65 years of age.

Exclusion criteria

Defined neurological or neurodegenerative disorder (e.g., history of head injury with loss of consciousness > 5 minutes, epilepsy, Alzheimer's disease);
Other psychiatric conditions (e.g., schizophrenia, schizoaffective disorder, bipolar disorder)
Current drug or alcohol use disorder, except for nicotine and marijuana
Adults unable to consent, pregnant women, prisoner
Non-English speakers
Patients that cannot tolerate Methohexital and Ketamine.